本文選題：慢性阻塞性肺�。–OPD） + 患者報(bào)告的臨床結(jié)局量表（PRO）��； 參考：《山西醫(yī)科大學(xué)》2012年碩士論文

【摘要】：研究目的：根據(jù)美國(guó)食品及藥物管理局（FDA）規(guī)定的PRO量表制作原則與流程，從患者角度編制基于慢性阻塞性肺病患者報(bào)告的臨床結(jié)局評(píng)價(jià)量表（PRO量表），通過(guò)預(yù)調(diào)查以及大樣本的臨床正式調(diào)查，修訂量表，并對(duì)其計(jì)量心理學(xué)特征做出評(píng)價(jià)。 研究方法：遵循國(guó)際量表研制的流程規(guī)范，以慢性阻塞性肺病的理論知識(shí)為基礎(chǔ)，通過(guò)文獻(xiàn)查閱以及患者訪談、借鑒國(guó)內(nèi)外相關(guān)量表形成量表域結(jié)構(gòu)及條目池，之后由多位各領(lǐng)域?qū)＜覍?duì)條目池進(jìn)行修改，做小范圍調(diào)查進(jìn)行語(yǔ)言調(diào)試，形成初量表。通過(guò)預(yù)調(diào)查對(duì)條目進(jìn)行初步篩選和調(diào)整，形成正式量表。于醫(yī)院及社區(qū)展開(kāi)現(xiàn)場(chǎng)調(diào)查獲得樣本，評(píng)價(jià)終量表的信度、效度、反應(yīng)度等各指標(biāo)，經(jīng)過(guò)調(diào)整，形成終量表。 研究結(jié)果：1．形成基于慢性阻塞性肺病患者報(bào)告的臨床結(jié)局評(píng)價(jià)量表。量表由生理領(lǐng)域、心理領(lǐng)域、社會(huì)領(lǐng)域、治療領(lǐng)域4個(gè)一級(jí)維度組成，其中生理領(lǐng)域包括特異性癥狀、全身癥狀、獨(dú)立性3個(gè)方面；心理領(lǐng)域包括焦慮、抑郁2個(gè)方面；社會(huì)領(lǐng)域包括疾病認(rèn)知、疾病對(duì)社會(huì)活動(dòng)的影響、社會(huì)支持度3個(gè)方面；治療領(lǐng)域包括依從性、藥物副作用、滿(mǎn)意度3個(gè)方面，共11個(gè)二級(jí)維度。量表包含52個(gè)條目。2．對(duì)395例有效數(shù)據(jù)進(jìn)行分析。結(jié)果顯示該量表評(píng)價(jià)慢性阻塞性肺病患者具有較好的信度、效度、反應(yīng)度及臨床可行性。分半信度系數(shù)：生理領(lǐng)域0.762，心理領(lǐng)域0.865，社會(huì)領(lǐng)域0.755，治療領(lǐng)域0.862，整個(gè)量表0.757�？死拾秃障禂�(shù)：生理領(lǐng)域0.888，，心理領(lǐng)域0.898，社會(huì)領(lǐng)域0.704，治療領(lǐng)域0.696，整個(gè)量表0.923。 研究結(jié)論：根據(jù)FDA的規(guī)定，我們研制出基于慢性阻塞性肺病患者報(bào)告的臨床結(jié)局評(píng)價(jià)量表。將經(jīng)典測(cè)量方法和項(xiàng)目反應(yīng)理論結(jié)合對(duì)量表進(jìn)行評(píng)價(jià)。結(jié)果表明：該量表具有較好的信度、效度、反應(yīng)度和臨床可行性,可以作為慢性阻塞性肺病臨床療效評(píng)價(jià)研究的工具。
[Abstract]:Objective: according to the principle and procedure of the pro scale made by the Food and Drug Administration (FDA), The clinical outcome evaluation scale (pro) based on the report of patients with chronic obstructive pulmonary disease (COPD) was compiled from the patient's point of view. The scale was revised by pre-investigation and a large sample of clinical formal investigation, and the characteristics of econometric psychology were evaluated. Methods: according to the procedure of international scale development, based on the theoretical knowledge of chronic obstructive pulmonary disease (COPD), through literature review and patient interviews, the scale domain structure and item pool were formed by referring to the relevant scales at home and abroad. After that, a number of experts in various fields modify the item pool, do a small survey to debug the language, and form a preliminary scale. Through preliminary screening and adjustment of items through pre-investigation, a formal scale was formed. Field investigation was carried out in hospitals and communities to obtain samples and evaluate the reliability, validity and response of the final scale, which were adjusted to form the final scale. Results: 1. A clinical outcome evaluation scale based on COPD patient reports was developed. The scale consists of four dimensions: physiological field, psychological field, social field and therapeutic field, in which the physiological field includes three aspects: specific symptom, systemic symptom, independence, anxiety and depression. The social domain includes disease cognition, the influence of disease on social activities, social support degree, and the treatment field includes compliance, side effects of drugs and satisfaction, which are 11 second-order dimensions. The data of 395 cases were analyzed. The results showed that the scale had good reliability, validity, response and clinical feasibility in evaluating patients with chronic obstructive pulmonary disease (COPD). Split-half reliability coefficient: physiological field 0.762, psychological field 0.865, social field 0.755, treatment field 0.862. the whole scale 0.757. Cronbach coefficient: physiological field 0.888, psychological field 0.898, social field 0.704, therapeutic field 0.696, whole scale 0.923. Conclusion: in accordance with FDA guidelines, we developed a clinical outcome evaluation scale based on chronic obstructive pulmonary disease (COPD) reports. The classical measurement method and item response theory were combined to evaluate the scale. The results showed that the scale had good reliability, validity, response and clinical feasibility, and could be used as a tool to evaluate the clinical efficacy of chronic obstructive pulmonary disease (COPD).
【學(xué)位授予單位】：山西醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2012
【分類(lèi)號(hào)】：R563.9

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 劉鳳斌;郭麗;劉小斌;;建立中醫(yī)重癥肌無(wú)力PRO量表的理論結(jié)構(gòu)模型構(gòu)想的探討[J];新中醫(yī);2009年09期

2 阮新民,林宇,江巍,胡佳心,陳秋雄,吳煥林,陳伯鈞,周漢槎,黃春林;中藥對(duì)冠狀動(dòng)脈搭橋術(shù)后患者生活質(zhì)量的改善作用[J];廣州中醫(yī)藥大學(xué)學(xué)報(bào);2004年01期

3 段錦繡;劉保延;趙宏;劉志順;;淺談中醫(yī)藥PRO量表的研制[J];天津中醫(yī)藥;2009年06期

4 陳麗敏,劉青,陳曉東;慢性阻塞性肺病外周血IL—8及中性粒細(xì)胞水平探討[J];現(xiàn)代康復(fù);2000年07期

5 范大超;;PRO量表在新藥臨床試驗(yàn)中的應(yīng)用[J];中國(guó)處方藥;2009年11期

6 ;慢性阻塞性肺疾病診治指南[J];中華結(jié)核和呼吸雜志;2002年08期

7 蔡柏薔,張弘;慢性阻塞性肺疾病患者病情和治療療效的評(píng)估[J];中華結(jié)核和呼吸雜志;2005年07期

8 彭敏,蔡柏薔;美國(guó)胸科協(xié)會(huì)和歐洲呼吸協(xié)會(huì)對(duì)慢性阻塞性肺疾病診治指南的修訂[J];中華內(nèi)科雜志;2005年05期

9 蔡柏薔;;慢性阻塞性肺疾病患者的生活質(zhì)量評(píng)估[J];中國(guó)康復(fù)理論與實(shí)踐;2009年05期

10 劉鳳斌,方積乾,潘志恒,李瓊,劉小玲,郝元濤;用于電腦專(zhuān)家診斷系統(tǒng)的脾胃病辨證量表的研制[J];中山醫(yī)科大學(xué)學(xué)報(bào);2000年S1期

本文編號(hào)：2114724